30 exclusive Chinese medicine is strong pediatric medicine, slow-disease medicine "over the screen"

Pharmaceutical Network January 13th, 2020 edition of the National Health Insurance Directory was officially released, 119 drugs (79 chemical drugs, 40 traditional Chinese medicine) negotiations were successful, of which 96 are exclusive drugs (30 are traditional Chinese medicine).
meters of intranet data show that the average decline of 30 exclusive Chinese medicine more than 25%, in 2019 China's public medical institutions terminal sales of more than 1 billion yuan (2020H1 nearly 500 million yuan), most varieties of sales are small, pediatric drugs, chronic drugs "over the screen";
series of new policies, the 400 billion Chinese medicine market is in urgent need of new growth points, innovative drugs are expected to open a breakthrough. Table
1: The exclusive Chinese medicine (unit: yuan) included in the 2020 edition of the National Health Insurance Directory Source: National Health Insurance Administration, Minnet database 119 drugs negotiated into the 2020 edition of the National Health Insurance, the average price reduction of 50.64 percent, of which 30 are exclusive Chinese medicine.
compared with the 2020 minimum list price/winning bid price compared to the 2020 medicare payment price, the average decline of 30 exclusive Chinese medicines was more than 25%, of which, the total alkaloid tablets (-59.33%) and the dredging particles (-55) .09%), heart-thulin injection (-60.7%), quinoa saponin capsule (-62.79%), five tiger oral solution (-66.86%) decreased by more than 50%, and Arinin particles decreased by less than 10%.
more than 1 billion market catch-up volume, slow-disease drugs, pediatric drugs bright-eye rice intranet data show that 30 exclusive Chinese medicine in 2019 China's urban public hospitals, county-level public hospitals, urban community centers and township hospitals (referred to as China's public medical institutions) The total sales of the terminal exceeded 1 billion yuan (nearly 500 million yuan in the first half of 2020), of which more than 100 million yuan was sales of Aer Ning particles (Golden Tibetan medicine), heart-pulsed injections (Yunnan Teng Pharmaceuticals), and Rui Treasure Tablets (Gansu Qizheng Tibetan Medicine).
From the growth rate, 2019 gold and silver flower oral solution (True O gold and silver flower medicine), Chai Wei Qingning capsule (Yangzijiang Jiangsu Longfengtang Chinese medicine), dredging particles (Gillin Huakang Pharmaceuticals), Qing stomach painkillers (Gillin Huakang) Pharmaceuticals), Xiong bile shu liver bile capsules (Yunnan famous pharmaceutical industry) surged by more than 50%, of which Chai Yu Qingning capsules soared by more than 140%;
, most of the 30 exclusive Chinese medicine sales market is small, and some show a decline in sales.
than the non-exclusive varieties, the exclusive varieties of new health insurance catalog, the benefits of pharmaceutical companies are more obvious.
30 exclusive Chinese medicines to advance into the new health insurance is expected to achieve volume, more than 1 billion market will usher in a new round of growth.
figure 1: 30 exclusive Chinese medicine treatment category 30 exclusive Chinese medicine covers 8 treatment categories, digestive disease medication with 26.67 percent of the proportion (8 varieties) in the first place, heart and brain Vascular disease medication was followed by 23.33% (7 varieties), followed by pediatric medication and respiratory disease medication with 16.67% (5 varieties).
In recent years, under the effect of people's lifestyle changes, increased life pressure, increasing aging and other factors, diabetes, hypertension, hyperlipidemia, stroke, coronary heart disease and other chronic disease patients increased, promote the expansion of the relevant market capacity, the policy is also tilted towards related treatment drugs, such as slow-disease Internet re-diagnosis into health insurance payments, the national base medicine slow-disease medication or free of charge, the new version of the medical insurance directory also included a lot of slow-disease drugs, and a number of related to the growth of the market.
In addition, the state attaches great importance to the protection of children's drug use, so far in 2016 has issued three batches to encourage research and development to declare children's drug list, the new version of the medical insurance directory has also added a variety of children's drugs, including calf Huang Qingxin (Shandong Guangyutang National Medicine), children Jing apricot cough particles (Hunan Fangsheng Pharmaceuticals), Anning particles (Golden Tibetan medicine), dredging particles (Gilling Huakang Pharmaceuticals), hemp anti-spasm particles (Tiansli) and other exclusive varieties, is expected to further stimulate the expansion of the market for chinese medicine in pediatrics.
Jichuan, Qi Zheng Tibetan medicine... 6 enterprises lit up, 3 "lucky" birth table 2: the number of new medical insurance exclusive Chinese medicine into 2 enterprises 30 exclusive Chinese medicine involving a total of 24 enterprises (in group count), Jichuan Pharmaceuticals, Qizheng Tibetan Pharmaceuticals, Shaanxi Jianmin Pharmaceuticals, Shenwei Pharmaceuticals, Changchun Gaoxin, Kangchen Pharmaceuticals 6 enterprises (including subsidiaries) have 2 exclusive Chinese medicine into the new health insurance.
Jichuan Pharmaceuticals' Ganhai gastric kang capsules, Sichuan Qing brain particles medical insurance is not limited, and Kawakubo clear brain particles are the only exclusive nervous system medicine; Pill health insurance is not limited, and serum pills are the only exclusive gynaecological Chinese medicine, Changchun high-new dredging particles, gastric painkillers in 2019 China's public medical institutions terminal sales growth rate of more than 60%.
2020 version of the health insurance catalog adjustment to achieve a "seamless interface" between drug approval and medical insurance review, according to combing, the successful negotiation of 96 exclusive drugs, 16 of the newly approved in 2020 (in terms of status start date), become a rapid entry into the national health insurance directory of the "lucky", of which 3 are Chinese medicine, respectively, mulberry total alkaloid tablets, bone pain gel, even cough tablets.
Sangzhi Total Alkaloid Tablets, a new anti-diabetic natural drug with independent intellectual property rights jointly developed by Beijing Wu and Boao Pharmaceuticals and the Institute of Pharmaceutical Research of the Chinese Academy of Medical Sciences, was approved for sale in March 2020, the first new chinese medicine for diabetes approved in nearly 10 years.
its action is similar to Acapo sugar, but the adverse reaction of gastrointestinal bloating is significantly reduced.
rib pain relief gel is a new class 6.1 drug of Chinese medicine, with live blood gas, rheumatism dehumidification, the effect of pain relief, used for knee osteoarthritis nephroidal vein hysteresis symptoms improvement.
Pharmaceuticals said that the rib pain gel for the company in 2020 newly approved listed drugs, has not yet carried out mass production and sales.
because the variety is the exclusive variety, and the drug route has advantages, this time included in the health insurance is expected to play a positive role in sales in the future.
Lianhua Qing cough tablets are the new patented Chinese medicine approved by Ling Pharmaceuticals in May 2020, which has the effect of venting pulmonary fever and sputum cough, and is used for coughing, coughing and so on caused by acute trachea-bronchitis sputum fever lung certificate.
Toling Pharmaceuticals said that lianhua qing cough tablets into the new version of health insurance, help to enhance the company's market competitiveness in the field of respiratory diseases, is expected to become the company's new business growth point, the future will increase the research and development of innovative Chinese medicine.
400 billion market is in urgent need of new growth points, innovative Chinese medicine is expected to open a breakthrough in recent years, by the adjustment of medical insurance policy, hospital rational drug policy gradually refined and other effects, oral Chinese medicine market growth continued to slow down, the chinese medicine injection market declined significantly, making the entire Chinese medicine market growth pressure;
if Chinese medicine is incorporated into the national market, it will have a certain impact on its market.
figure 2: China's public medical institutions and China's urban physical pharmacy terminal sales of Chinese medicine (units: 100 million yuan) Source: Mi Net database Mienet data show that in 2019 China's public medical institutions terminal and China's urban physical pharmacy terminal Chinese medicine market size of nearly 400 billion yuan, down 1.13% YoY, the first decline in growth rate, can be seen in the development of Chinese medicine in urgent need of new breakthroughs.
On December 25, 2020, the State Drug Administration, in its Implementation Opinion on Promoting the Innovation and Development of Traditional Chinese Medicine, mentioned that applications for new Chinese medicines for major diseases, rare diseases prevention and treatment, clinical urgent needs and market shortages, or new Chinese medicines belonging to children's medicines are subject to priority review and approval.
If the treatment of a serious life-threatening disease and there is no effective treatment means, as well as the competent department of health and health or Chinese medicine under the State Council, is determined to be an urgent need for Chinese medicine, the clinical trial of the drug has data or high-quality Chinese medicine human experience evidence shows efficacy and can predict its clinical value, it may be approved with conditions.
to implement special approval for the increased functional treatment of listed Chinese medicines required for emergencies in major public health emergencies.
, it can be seen that the state to encourage the development of Traditional Chinese medicine is still the general trend, but only the exact efficacy, clinically urgent need, reasonable price of drugs can continue to flourish.
series of policies, more and more enterprises have recognized the importance of innovation, and increased efforts to research and development of innovative Chinese medicine.
form 3: 2018-2020 application for the listing of new Chinese medicine source: MiNet MED2.0 China Drug Review Database MiNet data show that in the past three years, 15 innovative Chinese medicine submitted applications for listing, four of which have been approved for listing, and have been included in the 2020 edition of the national health insurance directory.
With more and more clinically urgently needed and precisely effective innovative Chinese medicines have been approved for market, injecting new impetus and sources into the Chinese medicine market, the future is expected to become a new growth point of the Chinese medicine market.
sources: Minet database, National Health Insurance Administration, etc